145 related articles for article (PubMed ID: 14741566)
1. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation.
Chen X; Park R; Shahinian AH; Bading JR; Conti PS
Nucl Med Biol; 2004 Jan; 31(1):11-9. PubMed ID: 14741566
[TBL] [Abstract][Full Text] [Related]
2. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
3. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide.
Chen X; Park R; Hou Y; Khankaldyyan V; Gonzales-Gomez I; Tohme M; Bading JR; Laug WE; Conti PS
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1081-9. PubMed ID: 15118844
[TBL] [Abstract][Full Text] [Related]
4. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.
Chen X; Park R; Shahinian AH; Tohme M; Khankaldyyan V; Bozorgzadeh MH; Bading JR; Moats R; Laug WE; Conti PS
Nucl Med Biol; 2004 Feb; 31(2):179-89. PubMed ID: 15013483
[TBL] [Abstract][Full Text] [Related]
5. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide.
Chen X; Park R; Tohme M; Shahinian AH; Bading JR; Conti PS
Bioconjug Chem; 2004; 15(1):41-9. PubMed ID: 14733582
[TBL] [Abstract][Full Text] [Related]
6. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression.
Wu Z; Li ZB; Cai W; He L; Chin FT; Li F; Chen X
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1823-1831. PubMed ID: 17492285
[TBL] [Abstract][Full Text] [Related]
7. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs.
Lee KH; Jung KH; Song SH; Kim DH; Lee BC; Sung HJ; Han YM; Choe YS; Chi DY; Kim BT
J Nucl Med; 2005 Mar; 46(3):472-8. PubMed ID: 15750161
[TBL] [Abstract][Full Text] [Related]
9. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.
Rangger C; Helbok A; von Guggenberg E; Sosabowski J; Radolf T; Prassl R; Andreae F; Thurner GC; Haubner R; Decristoforo C
Int J Nanomedicine; 2012; 7():5889-900. PubMed ID: 23226020
[TBL] [Abstract][Full Text] [Related]
10. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging.
Li ZB; Wu Z; Chen K; Ryu EK; Chen X
J Nucl Med; 2008 Mar; 49(3):453-61. PubMed ID: 18287274
[TBL] [Abstract][Full Text] [Related]
11. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
12. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide.
Chen X; Tohme M; Park R; Hou Y; Bading JR; Conti PS
Mol Imaging; 2004 Apr; 3(2):96-104. PubMed ID: 15296674
[TBL] [Abstract][Full Text] [Related]
13. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
[TBL] [Abstract][Full Text] [Related]
14. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
15. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
16. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
17. microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4).
Wu Z; Li ZB; Chen K; Cai W; He L; Chin FT; Li F; Chen X
J Nucl Med; 2007 Sep; 48(9):1536-44. PubMed ID: 17704249
[TBL] [Abstract][Full Text] [Related]
18. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
19. Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model.
Ahmadi M; Sancey L; Briat A; Riou L; Boturyn D; Dumy P; Fagret D; Ghezzi C; Vuillez JP
Cancer Biother Radiopharm; 2008 Dec; 23(6):691-700. PubMed ID: 19111043
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
